Quantcast
Last updated on April 20, 2014 at 19:30 EDT

Latest allergic asthma Stories

2013-09-09 00:21:15

Patients with baseline blood eosinophil counts above 0.1 cells/nL respond to treatment with CYT003 ZURICH, September 9, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today announced additional results of the phase 2a clinical trial with CYT003, a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. A post-hoc analysis of data published in the March issue of The Journal of Allergy and Clinical Immunology [1] are...

2013-07-23 08:29:17

6.8% Improvement in FEV1 Versus Placebo in Pre-Specified Th2 Biomarker Subset Representing Half of Treated Patients BOULDER, Colo., July 23, 2013 /PRNewswire/ -- Array BioPharma Inc. (NASDAQ: ARRY) today announced positive results from a placebo-controlled, randomized, double?blind Phase 2 trial in mild to moderate persistent allergic asthma for ARRY-502, an oral CRTh2 antagonist. ARRY-502 achieved the primary endpoint, significant improvement in pre-bronchodilator Forced...

2013-04-25 00:20:43

ZURICH, April 25, 2013 /PRNewswire/ --  -    Phase 2b clinical trial of CYT003 in allergic asthma on-going as planned  -    Cytos' VLP platform is basis for a phase 1 clinical trial with an Anti-lgE Vaccine partnered with and conducted by Pfizer...

2013-03-13 04:21:02

ZURICH, March 13, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today announced the publication of the results from its phase 2a clinical trial with CYT003-QbG10 (CYT003), a first-in-class immune modulator in clinical development as a potential new treatment for allergic asthma. The data are published in the March issue of The Journal of Allergy and Clinical Immunology (JACI) in the article entitled "The novel TLR-9 agonist QbG10 shows clinical efficacy in persistent...

2013-01-16 00:20:33

SCHLIEREN, Switzerland, January 16, 2013 /PRNewswire/ -- Cytos Biotechnology Ltd (SIX:CYTN) today announced an update on the Phase 2b clinical trial with its lead product candidate, CYT003, in allergic asthma. The clinical trial will recruit approximately 360 adult patients with moderate to severe allergic asthma not sufficiently controlled on current standard therapy. The study will be conducted at more than 90 centers in North America and Europe, and is expected to read out...

2012-10-08 23:20:28

ZURICH, Oct. 9, 2012 /PRNewswire/ -- Cytos Biotechnology Ltd ("Cytos" or "the Company"), a Swiss biotech company focused on the development of CYT003 in allergic asthma, announced today the appointment of Dr. Christian Itin as Chief Executive Officer. As announced on 29 May 2012, the Board will propose to the Company's shareholders that Dr. Itin be elected as member of the Board, and it is intended that he will succeed Dr. Thomas Hecht as Chairman of the Board of Directors as of an...

2012-09-05 02:31:39

SOUTH SAN FRANCISCO, Calif., Sept. 5, 2012 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that it has commenced Phase 2 clinical studies with two of the company's most advanced proprietary therapeutic product candidates. R343 is an inhaled SYK inhibitor that is being evaluated as a potential treatment for allergic asthma. R333 is a topical JAK/SYK inhibitor aimed at treating various phases of discoid lupus erythematosus (DLE, or lupus of the skin). To view the...

2012-07-05 10:35:24

Reprogramming asthma-promoting immune cells in mice diminishes airway damage and inflammation, and could potentially lead to new treatments for people with asthma, researchers have found. The researchers were able to reprogram the asthma-promoting cells (called Th2 (T-helper 2) cells) after identifying an enzyme that modifies the DNA of these cells. The enzyme could be a target for the development of new treatments for chronic inflammatory diseases, in particular allergic asthma, caused by...

2012-03-21 05:46:18

(Ivanhoe Newswire) — Allergic asthma affects more than 100 million people worldwide and its prevalence is increasing on average by 50% every decade! A study suggests that widely used antibiotics may be the cause for the increased incidences and severity of allergic asthma in children. University of British Columbia study is the first of its kind to link kids´ exposure to certain antibiotics, like those in developed countries, to allergic asthma. The human gut is colonized by...

2012-03-16 16:52:14

Widely used antibiotics may increase incidence and severity of allergic asthma in early life, according to a University of British Columbia study. The study, published today in the journal EMBO reports, shows that certain antibiotics that affect intestinal bacteria also had a profound impact on allergic asthma. "It has long been suspected that kids exposed to more antibiotics — like those in developed countries — are more prone to allergic asthma," says the study's author,...